The invention relates to a phytotherapeutic agent for the treatment of skin lesions and morbid skin changes. In particular, it should be suitable for functioning as an effective therapeutic agent for the treatment of herpes simplex without significant side effects.The phytotherapeutic agent consists of an extract of components extractable from sage, (Salvia officinalis), ribwort plantain (Plantago lanceolata), greater plantain (Plantago major) and mistletoe (Viscum album).

Therapeutic composition for the treatment of skin lesions and methods for its preparation

A drug and/or pharmaceutical composition comprising recombinant mistletoe lectins for treating metastatic tumors, including malignant melanoma such as stage IV malignant melanoma, and use of said drug, particularly in select patient populations, are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain or fragments thereof. Alternatively, the recombinant mistletoe lectin polypeptides can be mistletoe lectin B-chain or fragments thereof. The drug can be used for the treatment of stages III and IV of a metastatic tumor or skin cancer, as well as to treat non-responders and therapeutic failures of a standard tumor therapy. The drug can be used in a dosage in a range of 3-7 ng recombinant mistletoe lectin per kg body weight. The dosage of the recombinant mistletoe lectin can also be 200-500 ng, independently of body weight. The drug can be administered once a week, or more frequently.

viscum articulatum/antifungal

Therapeutic composition for the treatment of skin lesions and methods for its preparation

Drug containing recombinant mistletoe lectins for treating malignant melanoma

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht